ReviewReviews in cardiovascular medicine2023
C-Reactive Protein in Atherosclerosis-More than a Biomarker, but not Just a Culprit.
Review in Reviews in cardiovascular medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Hs-CRP as a biomarker for atherosclerosis progression and cardiovascular risk: a systematic review.PeerJ · 2026Pooled it
- Navigating immunity to predict cardiovascular risk.European journal of preventive cardiology · 2026Article
- Beyond the Usual Suspects: A Narrative Review of High-Yield Non-Traditional Risk Factors for Atherosclerosis.Journal of clinical medicine · 2026Review
- Cardiovascular risk in inflammatory bowel disease: focus on lipids and visceral adipose tissue.Frontiers in endocrinology · 2026Review
- Prognostic value of CALLY index in combination with the GRACE score among patients with acute myocardial infarction: a retrospective cohort study.Frontiers in cardiovascular medicine · 2026Article
- Relationship between C-reactive protein triglyceride glucose index and cardiovascular disease risk: a cross-sectional analysis with machine learning.BMC medical informatics and decision making · 2025Article
- Role of anti-inflammatory agent colchicine in atherosclerotic cardiovascular disease.World journal of clinical cases · 2025Review
- Assessment of Serum Endocan Levels and Their Associations with Arterial Stiffness Parameters in Young Patients with Systemic Lupus Erythematosus.Journal of clinical medicine · 2025Article
- Immune Dysregulation Connecting Type 2 Diabetes and Cardiovascular Complications.Life (Basel, Switzerland) · 2025Review
- Associations between cardiometabolic indices and heart disease among elderly and middle-aged Chinese individuals: a retrospective longitudinal study.Scientific reports · 2025Observational
- Association between cardiovascular-kidney-metabolic health and rheumatoid arthritis prevalence: A cross-sectional study.Medicine · 2025Article
- Cardiovascular disease risk factors are associated with conventional lipids and apolipoproteins in South African adults of African ancestry.Lipids in health and disease · 2025Article
- C-reactive protein-induced injury inMicrobiology spectrum · 2025Article
- Effect of exercise on postprandial lipaemia in children with sickle cell disease.Frontiers in sports and active living · 2025Article
- Role of C-Reactive Protein, An Inflammatory Biomarker in The Development of Atherosclerosis and Its Treatment.The International journal of angiology : official publication of the International College of Angiology, Inc · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
C-reactive protein (CRP) is a pentraxin that is mainly synthesized in the liver in response to inflammatory cytokines. It exists in two functionally and structurally distinct isoforms. The first is a highly pro-inflammatory and mostly tissue-bound monomeric isoform (mCRP). The second is circulating pentameric CRP (pCRP), which also serves as a substrate for the formation of mCRP. CRP is elevated during inflammatory conditions and is associated with a higher risk of cardiovascular disease. The aim of this review is to examine the current state of knowledge regarding the role of these two distinct CRP isoforms on atherogenesis. This should allow further evaluation of CRP as a potential therapeutic target for atherosclerosis. While it seems clear that CRP should be used as a therapeutic target for atherosclerosis and cardiovascular disease, questions remain about how this can be achieved. Current data suggests that CRP is more than just a biomarker of atherosclerosis and cardiovascular disease. Indeed, recent evidence shows that mCRP in particular is strongly atherogenic, whereas pCRP may be partially protective against atherogenesis. Thus, further investigation is needed to determine how the two CRP isoforms contribute to atherogenesis and the development of cardiovascular disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.